Analysts Offer Predictions for aTyr Pharma Inc’s Q1 2019 Earnings (LIFE)

aTyr Pharma Inc (NASDAQ:LIFE) – Research analysts at William Blair issued their Q1 2019 earnings per share (EPS) estimates for aTyr Pharma in a research note issued to investors on Monday. William Blair analyst Y. Xu expects that the biotechnology company will earn ($0.37) per share for the quarter. William Blair also issued estimates for aTyr Pharma’s Q2 2019 earnings at ($0.38) EPS, Q3 2019 earnings at ($0.40) EPS and Q4 2019 earnings at ($0.42) EPS.

How to Become a New Pot Stock Millionaire

A number of other brokerages have also recently commented on LIFE. Zacks Investment Research cut aTyr Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. ValuEngine downgraded aTyr Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Finally, JPMorgan Chase & Co. downgraded aTyr Pharma from a “neutral” rating to an “underweight” rating in a report on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. aTyr Pharma has a consensus rating of “Hold” and a consensus target price of $4.75.

Shares of LIFE stock traded up $0.02 during midday trading on Wednesday, hitting $3.02. The company had a trading volume of 12,827 shares, compared to its average volume of 47,265. The stock has a market cap of $86.41, a PE ratio of -1.59 and a beta of 3.54. The company has a current ratio of 8.19, a quick ratio of 9.49 and a debt-to-equity ratio of 0.23. aTyr Pharma has a 52 week low of $2.30 and a 52 week high of $6.50.

Hedge funds have recently bought and sold shares of the company. Deutsche Bank AG purchased a new position in shares of aTyr Pharma in the fourth quarter worth $199,000. Dimensional Fund Advisors LP raised its stake in shares of aTyr Pharma by 44.1% in the third quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 25,676 shares during the last quarter. Victory Capital Management Inc. purchased a new position in shares of aTyr Pharma in the third quarter worth $455,000. Renaissance Technologies LLC increased its position in aTyr Pharma by 143.2% during the fourth quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock valued at $978,000 after acquiring an additional 164,500 shares during the last quarter. Finally, Artal Group S.A. increased its position in aTyr Pharma by 100.0% during the fourth quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock valued at $1,750,000 after acquiring an additional 250,000 shares during the last quarter. Hedge funds and other institutional investors own 58.65% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Analysts Offer Predictions for aTyr Pharma Inc’s Q1 2019 Earnings (LIFE)” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3288925/analysts-offer-predictions-for-atyr-pharma-incs-q1-2019-earnings-life.html.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Earnings History and Estimates for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Valeura Energy  Insider Sells C$1,580,806.08 in Stock
Valeura Energy Insider Sells C$1,580,806.08 in Stock
Robert Half International  Trading 0.3% Higher  on Analyst Upgrade
Robert Half International Trading 0.3% Higher on Analyst Upgrade
Texas Instruments  Shares Gap Up  on Analyst Upgrade
Texas Instruments Shares Gap Up on Analyst Upgrade
Samuel Adams  Hits New 1-Year High and Low After Strong Earnings
Samuel Adams Hits New 1-Year High and Low After Strong Earnings
Peoples Financial Services  Announces  Earnings Results
Peoples Financial Services Announces Earnings Results
Tupperware Brands  Issues Q2 Earnings Guidance
Tupperware Brands Issues Q2 Earnings Guidance


© 2006-2018 Ticker Report. Google+.